Aspira Women’s Health (AWH) Set to Announce Quarterly Earnings on Thursday

Aspira Women’s Health (NASDAQ:AWH) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.28) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Aspira Women’s Health (NASDAQ:AWH) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.04. The firm had revenue of $2.42 million for the quarter, compared to analyst estimates of $2.60 million. During the same period in the previous year, the business posted ($0.28) earnings per share. On average, analysts expect Aspira Women’s Health to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aspira Women’s Health Price Performance

AWH stock opened at $0.86 on Thursday. Aspira Women’s Health has a fifty-two week low of $0.74 and a fifty-two week high of $5.65. The stock has a market capitalization of $13.81 million, a price-to-earnings ratio of -0.59 and a beta of 1.44. The business’s fifty day moving average price is $0.88 and its two-hundred day moving average price is $1.53.

Analysts Set New Price Targets

Several research firms have recently issued reports on AWH. Alliance Global Partners reduced their target price on Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating on the stock in a report on Wednesday, August 14th. StockNews.com began coverage on shares of Aspira Women’s Health in a report on Thursday. They issued a “hold” rating on the stock.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.